Acurx Pharmaceuticals Inc

Financial update: Acurx Pharmaceuticals reports a $15.8 million loss but strong liquidity and a 96 % Phase 2 cure rate for ibezapolstat, sparking a 218 % stock surge ahead of the Phase 3 trial for recurrent C. difficile.

Acurx Pharmaceuticals is facing market challenges, including a significant stock price decline, but continues to pursue its mission of developing innovative antibiotics to combat bacterial infections.

Acurx Pharmaceuticals is scheduled to release its Q1 2025 earnings on May 13, 2025, with investors eagerly awaiting the report to gain insights into the company’s financial health and stock performance.